» Articles » PMID: 27775646

Associated Clinical Disorders Diagnosed by Medical Specialists in 188 FMR1 Premutation Carriers Found in the Last 25 Years in the Spanish Basque Country: A Retrospective Study

Overview
Journal Genes (Basel)
Publisher MDPI
Date 2016 Oct 25
PMID 27775646
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Fragile X-associated tremor/ataxia syndrome (FXTAS) and fragile X-associated primary ovarian insufficiency (FXPOI) are definitely related to the fragile X mental retardation 1 () premutation (PM). Additional medical problems have also been associated with the PM, such as fibromyalgia, endocrine, and psychiatric disorders. To improve our understanding in the field, we reviewed all PM carriers and their reasons for any medical referrals from 104 fragile X families molecularly diagnosed in our laboratory and living in the Spanish Basque Country. After signing the written informed consent, we studied their electronic medical records in order to identify the disorders associated with the PM and their frequencies. We obtained clinical data in 188 PM carriers (147 women and 41 men). In women, the frequency of FXPOI (22.61%) was similar to that previously reported in PM carriers. In men, the frequency of definite FXTAS (28.57%) was lower than reported elsewhere. Furthermore, thyroid pathology was associated with the PM, the frequency of hypothyroidism being much higher in the studied region than in the general population (8.84% vs. 0.93%). Finally, we found no association with fibromyalgia or psychiatric problems. These findings represent another population contribution in this field and may be useful for the clinical management of PM carriers.

Citing Articles

Population-based FMR1 carrier screening among reproductive women.

Ain Q, Hwang Y, Yeung D, Panpaprai P, Iamurairat W, Chutimongkonkul W J Assist Reprod Genet. 2024; 41(11):3237-3243.

PMID: 39320553 PMC: 11621265. DOI: 10.1007/s10815-024-03242-2.


Effect of AGG Interruptions on Maternal Transmissions.

Villate O, Ibarluzea N, Maortua H, De la Hoz A, Rodriguez-Revenga L, Izquierdo-Alvarez S Front Mol Biosci. 2020; 7:135.

PMID: 32766278 PMC: 7381193. DOI: 10.3389/fmolb.2020.00135.


Neurological health and premature ovarian insufficiency - pathogenesis and clinical management.

Slopien R Prz Menopauzalny. 2018; 17(3):120-123.

PMID: 30356991 PMC: 6196775. DOI: 10.5114/pm.2018.78555.

References
1.
Tejada M, Garcia-Alegria E, Bilbao A, Martinez-Bouzas C, Beristain E, Poch M . Analysis of the molecular parameters that could predict the risk of manifesting premature ovarian failure in female premutation carriers of fragile X syndrome. Menopause. 2008; 15(5):945-9. DOI: 10.1097/gme.0b013e3181647762. View

2.
Coffey S, Cook K, Tartaglia N, Tassone F, Nguyen D, Pan R . Expanded clinical phenotype of women with the FMR1 premutation. Am J Med Genet A. 2008; 146A(8):1009-16. PMC: 2888464. DOI: 10.1002/ajmg.a.32060. View

3.
Sullivan S, Welt C, Sherman S . FMR1 and the continuum of primary ovarian insufficiency. Semin Reprod Med. 2011; 29(4):299-307. DOI: 10.1055/s-0031-1280915. View

4.
Garcia-Alegria E, Ibanez B, Minguez M, Poch M, Valiente A, Sanz-Parra A . Analysis of FMR1 gene expression in female premutation carriers using robust segmented linear regression models. RNA. 2007; 13(5):756-62. PMC: 1852810. DOI: 10.1261/rna.206307. View

5.
Mendoza N, Julia M, Galliano D, Coronado P, Diaz B, Fontes J . Spanish consensus on premature menopause. Maturitas. 2015; 80(2):220-5. DOI: 10.1016/j.maturitas.2014.11.007. View